索宝蛋白
(603231)
| 流通市值：18.34亿 | | | 总市值：33.05亿 |
| 流通股本：1.06亿 | | | 总股本：1.91亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 966,543,038.05 | 487,722,648.24 | 1,748,098,617.55 | 1,240,274,258.89 |
| 营业收入 | 966,543,038.05 | 487,722,648.24 | 1,748,098,617.55 | 1,240,274,258.89 |
| 二、营业总成本 | 892,937,641.66 | 452,399,406.08 | 1,539,225,328.77 | 1,075,039,263.85 |
| 营业成本 | 841,387,710.05 | 429,331,235.17 | 1,456,464,077.36 | 1,018,141,139.7 |
| 税金及附加 | 4,185,729.57 | 1,979,285.78 | 9,175,522.41 | 7,011,829.39 |
| 销售费用 | 11,447,967.94 | 4,798,787.58 | 26,063,266.38 | 17,461,119.65 |
| 管理费用 | 20,421,347.12 | 10,725,311.66 | 42,542,350.52 | 31,000,410.69 |
| 研发费用 | 7,305,835.75 | 1,633,326.81 | 8,122,201.16 | 5,469,908.59 |
| 财务费用 | 8,189,051.23 | 3,931,459.08 | -3,142,089.06 | -4,045,144.17 |
| 其中:利息费用 | 288,301.76 | 82,131.15 | 80,950.04 | 76,358.07 |
| 其中:利息收入 | 3,400,304.51 | 1,685,396.28 | 3,398,607.92 | 2,311,455.36 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 2,877,809.29 | 1,641,045.72 | 5,275,163.24 | 4,014,063.08 |
| 加:投资收益 | 955,983.47 | -297,488.78 | 2,838,359.07 | 1,581,978.35 |
| 资产处置收益 | 7,812.6 | 7,812.72 | 30,270.73 | -499,484.8 |
| 资产减值损失(新) | - | - | -2,347,992.39 | 16,626.41 |
| 信用减值损失(新) | -392,754.63 | -50,742.55 | -733,180.72 | -365,080.09 |
| 其他收益 | 3,216,620.95 | 951,624.37 | 13,105,910.78 | 7,066,622.65 |
| 四、营业利润 | 80,270,868.07 | 37,575,493.64 | 227,041,819.49 | 177,049,720.64 |
| 加:营业外收入 | 46,371.75 | 35,612.14 | 415,460.72 | 313,421.09 |
| 减:营业外支出 | 235,556.77 | 48,603.12 | 3,861,561.73 | 2,724,074.79 |
| 五、利润总额 | 80,081,683.05 | 37,562,502.66 | 223,595,718.48 | 174,639,066.94 |
| 减:所得税费用 | 12,969,796.23 | 6,064,964.39 | 33,879,367.2 | 27,951,169.53 |
| 六、净利润 | 67,111,886.82 | 31,497,538.27 | 189,716,351.28 | 146,687,897.41 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 67,111,886.82 | 31,497,538.27 | 189,716,351.28 | 146,687,897.41 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 68,136,837.2 | 31,781,029.71 | 189,716,351.28 | 146,687,897.41 |
| 少数股东损益 | -1,024,950.38 | -283,491.44 | - | - |
| 扣除非经常损益后的净利润 | 62,981,722.6 | 29,825,299.25 | 181,419,976.54 | 141,826,384.5 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.36 | 0.17 | 0.99 | 0.77 |
| (二)稀释每股收益 | 0.36 | 0.17 | 0.99 | 0.77 |
| 八、其他综合收益 | -24,530.74 | -8,507.93 | 11,335.77 | 21,391.58 |
| 归属于母公司股东的其他综合收益 | -24,530.74 | -8,507.93 | 11,335.77 | 21,391.58 |
| 九、综合收益总额 | 67,087,356.08 | 31,489,030.34 | 189,727,687.05 | 146,709,288.99 |
| 归属于母公司股东的综合收益总额 | 68,112,306.46 | 31,772,521.78 | 189,727,687.05 | 146,709,288.99 |
| 归属于少数股东的综合收益总额 | -1,024,950.38 | -283,491.44 | - | - |
| 公告日期 | 2026-08-28 | 2026-04-30 | 2026-04-24 | 2025-10-31 |
| 审计意见(境内) | | | 标准无保留意见 | |